Enlivex Therapeutics LtdNASDAQ:ENLV
- LAST PRICE1.5100
- TODAY'S CHANGE (%)0.0100 (0.6667%)
- Bid / Lots1.5100/ 1
- Ask / Lots1.5900/ 5
- Open / Previous Close1.5500 / 1.5000
- Day Range
- 52 Week Range
- Volume68,171
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ENLV |
|---|---|---|
| 09:32 ET | 3284 | 1.5304 |
| 09:34 ET | 3400 | 1.55 |
| 09:36 ET | 5300 | 1.55 |
| 09:38 ET | 3170 | 1.55 |
| 09:39 ET | 100 | 1.5537 |
| 09:41 ET | 840 | 1.53 |
| 09:45 ET | 1500 | 1.525 |
| 09:50 ET | 131 | 1.51 |
| 09:56 ET | 430 | 1.5164 |
| 10:10 ET | 102 | 1.51 |
| 10:19 ET | 100 | 1.5072 |
| 10:21 ET | 1430 | 1.5001 |
| 10:26 ET | 12129 | 1.44 |
| 10:28 ET | 977 | 1.4448 |
| 10:30 ET | 100 | 1.4401 |
| 10:32 ET | 100 | 1.48 |
| 10:37 ET | 2000 | 1.49 |
| 10:48 ET | 500 | 1.485 |
| 10:53 ET | 500 | 1.47 |
| 10:55 ET | 1200 | 1.47 |
| 11:04 ET | 100 | 1.4707 |
| 11:06 ET | 135 | 1.47 |
| 11:18 ET | 1900 | 1.45 |
| 11:20 ET | 4268 | 1.45 |
| 11:33 ET | 100 | 1.47 |
| 11:38 ET | 100 | 1.4726 |
| 11:40 ET | 500 | 1.47 |
| 11:45 ET | 1000 | 1.4799 |
| 11:47 ET | 551 | 1.49 |
| 12:21 ET | 100 | 1.49 |
| 12:23 ET | 650 | 1.48 |
| 12:32 ET | 248 | 1.4899 |
| 12:34 ET | 100 | 1.49 |
| 12:36 ET | 1000 | 1.5 |
| 12:59 ET | 134 | 1.53 |
| 01:35 ET | 200 | 1.505 |
| 01:39 ET | 949 | 1.4801 |
| 01:42 ET | 100 | 1.52 |
| 01:55 ET | 500 | 1.48 |
| 02:02 ET | 899 | 1.49 |
| 02:22 ET | 700 | 1.5 |
| 02:42 ET | 100 | 1.5043 |
| 02:49 ET | 100 | 1.4947 |
| 02:54 ET | 992 | 1.4701 |
| 02:56 ET | 700 | 1.5097 |
| 03:02 ET | 100 | 1.5038 |
| 03:14 ET | 700 | 1.495 |
| 03:18 ET | 100 | 1.5 |
| 03:30 ET | 100 | 1.495 |
| 03:36 ET | 5997 | 1.45 |
| 03:54 ET | 100 | 1.4977 |
| 03:56 ET | 302 | 1.495 |
| 03:59 ET | 3233 | 1.51 |
Sep 9, 2024
DJ Enlivex Therapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co., from 6:32AM ET on Monday Sep 09, 2024 by Dow Jones
6:32AM ET on Monday Sep 09, 2024 by Dow Jones
Aug 30, 2024
GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV, from 9:01AM ET on Friday Aug 30, 2024 by Dow Jones
9:01AM ET on Friday Aug 30, 2024 by Dow Jones
Aug 27, 2024
DJ Enlivex Therapeutics Initiated at Buy by EF Hutton, from 8:16AM ET on Tuesday Aug 27, 2024 by Dow Jones
8:16AM ET on Tuesday Aug 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Enlivex Therapeutics Ltd | 32.1M | -1.3x | --- |
AN2 Therapeutics Inc | 32.2M | -0.5x | --- |
Quince Therapeutics Inc | 32.9M | -0.7x | --- |
Acurx Pharmaceuticals Inc | 33.1M | -1.7x | --- |
Chemomab Therapeutics Ltd | 31.1M | -0.2x | --- |
Raphael Pharmaceutical Inc | 30.9M | -20.6x | --- |
Company Information
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Contact Information
- Headquarters
- 14 Einstein St.NESS-ZIONA, Israel 7403618
- Phone
- ---
- Fax
- ---
Executives
- Chief Executive Officer
- Oren Hershkovitz
- Executive Chairman of the Board
- Shai Novik
- Founder, Chief Scientific Officer and Medical Officer
- Dror Mevorach
- Chief Financial Officer
- Shachar Shlosberger
- Director
- Baruch Halpert
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $32.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 21.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.03 |
EPS | $-1.19 |
Book Value | $1.62 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
